hackint0sh/New-Dataset huggingface dataset:
Participants will be asked to participate in the 8-week Healing Within: Smoking Cessation Intervention for American Indian Women Experiencing Intimate Partner Violence, and complete interviews at baseline, end-of-treatment, and three months from the end of treatment. conditions: Smoking Cessation conditions: Cigarette Smoking studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 48 type: ESTIMATED name: Healing Within: Smoking Cessation Intervention for American Indian Women Experiencing Intimate Partner Violence measure: Trauma-Informed Practice Scales (TIPS) measure: Session Rating Scale (SRS) measure: Group Attitude Scale (GAS) measure: Biochemical verification of smoking status measure: Biochemical verification of smoking status measure: Biochemical verification of smoking status measure: Quit Attempts measure: Quit Attempts measure: Quit Attempts measure: Alcohol Use Disorders Identification Test (AUDIT) measure: Alcohol Use Disorders Identification Test (AUDIT) measure: Alcohol Use Disorders Identification Test (AUDIT) measure: NIDA ASSIST measure: NIDA ASSIST measure: NIDA ASSIST sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06357754 id: CA082-085 briefTitle: Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Secondary Malignancy overallStatus: RECRUITING date: 2023-10-06 date: 2038-10-06 date: 2038-10-06 date: 2024-04-10 date: 2024-04-10 name: Bristol-Myers Squibb class: INDUSTRY briefSummary: The purpose of this transgene assay testing service is to evaluate the tumor samples for transgene levels in patients who received a Bristol-Myers Squibb manufactured gene modified cellular therapy and have reported a qualifying secondary malignancy. conditions: Non-Hodgkin Lymphoma conditions: Chronic Lymphocytic Leukaemia conditions: Multiple Myeloma studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 50 type: ESTIMATED name: Idecabtagene vicleucel name: Lisocabtagene maraleucel measure: Participant in situ hybridization (ISH) transgene testing results measure: Participant insertion site (ISA) analysis testing results sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: CellCarta status: RECRUITING city: Antwerp country: Belgium lat: 51.21989 lon: 4.40346 hasResults: False
nctId: NCT06357741 id: 202286 briefTitle: Clinical Study of Desuzumab in the Treatment of Knee Osteoarthritis acronym: CSODITTOKO overallStatus: COMPLETED date: 2023-03-02 date: 2024-02-02 date: 2024-03-10 date: 2024-04-10 date: 2024-04-10 name: Wuhan Union Hospital, China class: OTHER briefSummary: As an activator of inhibiting nuclear factor kB receptor, denosumab affects osteoclast differentiation and development by inhibiting OPG/RANKL-RANK bone regulatory axis pathway. Therefore, denosumab is widely used in the treatment of bone diseases such as osteoporosis. Osteoporosis is closely related to knee osteoarthritis. RANKL-RANK pathway also plays a key role in the pathogenesis of knee osteoarthritis. Therefore, the investigators propose the hypothesis that denosumab can effectively treat knee osteoarthritis. conditions: Knee Osteoarthritis studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: PROSPECTIVE count: 8 type: ACTUAL name: Denosumab measure: Knee pain relief sex: ALL minimumAge: 45 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Wuhan Union Hospital city: Wuhan state: Hubei zip: 430000 country: China lat: 30.58333 lon: 114.26667 typeAbbrev: Prot hasProtocol: True hasSap: False hasIcf: False label: Study Protocol date: 2024-04-03 uploadDate: 2024-04-04T11:01 filename: Prot_000.pdf size: 398739 hasResults: False
nctId: NCT06357728 id: 2024/2035 briefTitle: Continuous Glucose Monitoring Glycemic cHAracterization During Pregnancy acronym: I-CHAP overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2025-04-01 date: 2025-12-01 date: 2024-04-10 date: 2024-04-10 name: KK Women's and Children's Hospital class: OTHER_GOV briefSummary: Our study named Integrated Continuous glucose monitoring glycemic cHAracterization during Pregnancy in comparison with oral glucose tolerance test (I-CHAP) aims to establish much needed preliminary evidence in our Asian population to show the capabilities of CGM use and its wealth of data for GDM diagnosis. This study aims to test the following aims and hypotheses in a single-armed intervention pilot trial study of pregnant women undergoing the oral glucose tolerance test:
Aim 3. To describe the acceptability of using the Dexcom G6 CGM as a diagnostic tool instead of the OGTT. The investigators hypothesize that a higher proportion of participants will report CGM to be more acceptable than the OGTT for GDM diagnosis. conditions: Gestational Diabetes conditions: Glucose Metabolism Disorders conditions: Metabolic Disease studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: All participants will be given a continuous glucose monitoring device to wear for 10 days before during and after the oral glucose tolerance test. primaryPurpose: BASIC_SCIENCE masking: NONE count: 60 type: ESTIMATED name: Continuous glucose monitoring measure: Maternal plasma glucose values measured by oral glucose tolerance test (OGTT) at 0-hour (mmol/L) measure: Maternal plasma glucose values measured by oral glucose tolerance test (OGTT) at 1-hour (mmol/L) measure: Maternal plasma glucose values measured by oral glucose tolerance test (OGTT) at 2-hour (mmol/L) measure: Maternal obstetric outcomes - Pre-eclampsia measure: Maternal obstetric outcomes- Pregnancy-induced hypertension measure: Maternal obstetric outcomes - C-section measure: Neonatal outcomes- Large-for-gestational-age measure: Neonatal outcomes-Birth weigh measure: Neonatal outcomes- Small-for-gestational-age measure: Neonatal outcomes-Pre-term birth measure: Neonatal outcomes-Neonatal hypoglycaemia measure: Types of treatment received for gestational diabetes diagnosis sex: FEMALE minimumAge: 21 Years maximumAge: 45 Years stdAges: ADULT typeAbbrev: Prot_SAP_ICF hasProtocol: True hasSap: True hasIcf: True label: Study Protocol, Statistical Analysis Plan, and Informed Consent Form date: 2024-02-20 uploadDate: 2024-03-18T04:35 filename: Prot_SAP_ICF_000.pdf size: 218503 hasResults: False
nctId: NCT06357715 id: 2021/373/HP briefTitle: Effectiveness of Neurodynamic Sliding Mobilisation in the "Slump" Position in Relation to the Perceptible Pain Threshold in Asymptomatic People acronym: SPEAKER 2 overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2024-05-09 date: 2026-05-09 date: 2024-04-10 date: 2024-04-10 name: University Hospital, Rouen class: OTHER briefSummary: According to the French National Health Agency, the use of manual therapy techniques is "possible" \[grade B\] as part of a multimodal combination of treatments for low back pain. These include so-called "neurodynamic" neural mobilisations, which aim in particular to desensitise the pain system and activate descending inhibitory pathways, with effects on pain and function in patients with nerve-related low back pain. Most of the available evidence does not explain the mechanisms involved in neural mobilisation in the slump position. Pain reduction is observed in more areas of the body with sliding techniques than with traction techniques.
In this cross-over, randomised controlled trial, we therefore hypothesise that the neurodynamic sliding technique in the slump position acts on mechanisms linked to central pain modulation processes conditions: Voluntary studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER primaryPurpose: TREATMENT masking: SINGLE maskingDescription: the second physiotherapist who evaluate the pressure pain whoMasked: OUTCOMES_ASSESSOR count: 54 type: ESTIMATED name: "slump"position name: no" slump" position measure: Difference in pressure at the moment when the volunteer indicates that the sensation of pressure becomes pain sex: ALL minimumAge: 30 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06357702 id: 81313 id: K23DE031807 type: NIH link: https://reporter.nih.gov/quickSearch/K23DE031807 briefTitle: K23- Physical Self Regulation vs Placebo overallStatus: RECRUITING date: 2024-04-04 date: 2028-06-01 date: 2028-08-31 date: 2024-04-10 date: 2024-04-15 name: Ian Boggero, PhD class: OTHER name: National Institute of Dental and Craniofacial Research (NIDCR) briefSummary: This study will use a between-person design. Participants will be treatment-seeking patients with chronic masticatory muscle pain. Participants who are eligible for the study and consent to participate will be randomly assigned to receive a brief behavioral intervention for chronic orofacial pain called Physical Self-Regulation or a control intervention. Interventions will be administered via telehealth in both arms. Both interventions will consist of 2 50-minute sessions scheduled approximately two weeks apart. Participants will be contacted two weeks and three months after completing the interventions to provide additional follow-up data. Investigators hypothesize that both PSR-TH and the control intervention will demonstrate strong feasibility (i.e., recruitment of at least 1 participant per week, \>75% retention, \>95% interventionist fidelity, and adequate acceptability, credibility, and burden). Investigators also hypothesize that specific biopsychosocial variables will moderate PSR-TH-related changes in outcomes, and that PSR-TH-related changes in perceived control over pain, self-efficacy, coping, parafunctional habits, and relaxation will mediate treatment effects. conditions: Temporomandibular Disorder studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 104 type: ESTIMATED name: Physical Self Regulation Telehealth name: Psycho-education Telehealth measure: Change in pain intensity measure: Change in pain interference measure: Change in quality of life measure: Recruitment rate measure: Retention rate measure: Interventionist Fidelity Session 1 measure: Interventionist Fidelity Session 2 measure: Treatment Acceptability measure: Treatment Credibility measure: Research Burden measure: Treatment Satisfaction sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Kentucky status: RECRUITING city: Lexington state: Kentucky zip: 40506 country: United States name: Ian Boggero, Ph.D. role: CONTACT phone: 859-562-3291 email: ian.boggero@uky.edu lat: 37.98869 lon: -84.47772 hasResults: False
nctId: NCT06357689 id: REC ID 6 briefTitle: Association of SNPs in Long Intergenic Noncoding RNA 00511 (LINC00511) With Breast Cancer Among the Egyptian Population overallStatus: COMPLETED date: 2021-10-24 date: 2023-03-11 date: 2023-04-29 date: 2024-04-10 date: 2024-04-10 name: Ain Shams University class: OTHER name: British University In Egypt briefSummary: Long non-coding RNAs (lncRNAs) play an important role in different types of cancer, including breast cancer, through regulation of gene expression and epigenetic signatures. Genetic variations such as single nucleotide polymorphisms (SNPs) in lncRNAs have been found to be associated with cancer. Our aim was to provide information about the role of LINC00511 SNPs (rs11657109 or rs17780195 or rs9906859, rs4432291 and rs1558535) in breast cancer susceptibility in the Egyptian population. conditions: Breast Cancer studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: RETROSPECTIVE count: 417 type: ACTUAL measure: Investigating the relationship of the genotypes of each SNP of the LINC00511 SNPs (rs11657109 or rs17780195 or rs9906859 or rs4432291 and rs1558535) with either increased or decreased risk of breast cancer or no effect in the Egyptian population measure: Finding out the association between LINC00511 SNPs (rs11657109 or rs17780195 or rs9906859 or rs4432291 and rs1558535) and Estrogen receptor measure: Finding out the association between LINC00511 SNPs (rs11657109 or rs17780195 or rs9906859 or rs4432291 and rs1558535) and Progesterone receptor measure: Finding out the association between LINC00511 SNPs (rs11657109 or rs17780195 or rs9906859 or rs4432291 and rs1558535) and HER2 status measure: Finding out the association between LINC00511 SNPs (rs11657109 or rs17780195 or rs9906859 or rs4432291 and rs1558535) and tumor stage measure: Finding out the association between LINC00511 SNPs (rs11657109 or rs17780195 or rs9906859 or rs4432291 and rs1558535) and tumor grade measure: Finding out the association between LINC00511 SNPs (rs11657109 or rs17780195 or rs9906859 or rs4432291 and rs1558535) and lymph node metastasis sex: FEMALE minimumAge: 20 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Faculty of pharmacy, Ain Shams University, Advanced Biochemisrty Research Lab city: Cairo country: Egypt lat: 30.06263 lon: 31.24967 facility: Faculty of Pharmacy, The British University in Egypt, Pharmacology and Biochemistry Research lab city: Cairo country: Egypt lat: 30.06263 lon: 31.24967 hasResults: False
nctId: NCT06357676 id: STUDY00025355 id: NCI-2024-01208 type: REGISTRY domain: CTRP (Clinical Trial Reporting Program) id: STUDY00025355 type: OTHER domain: OHSU Knight Cancer Institute briefTitle: Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2027-05-01 date: 2029-05-01 date: 2024-04-10 date: 2024-04-10 name: OHSU Knight Cancer Institute class: OTHER name: Oregon Health and Science University name: Genentech, Inc. briefSummary: This phase IB/II trial tests the safety, side effects and effectiveness of glofitamab plus ibrutinib with obinutuzumab for the treatment of patients with mantle cell lymphoma (MCL). Glofitamab is in a class of medications called bispecific monoclonal antibodies. It works by killing cancer cells. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). In the body, glofitamab binds to a receptor called CD3 on T-cells (a type of immune cells) and a receptor called CD20 on B-cells, a receptor that is often over-expressed on the surface of cancerous B-cells. When glofitamab binds to CD3 and CD20 receptors, it causes an immune response against the CD20-expressing cancerous B-cells. Ibrutinib is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps stop the spread of cancer cells. Obinutuzumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Glofitamab plus ibrutinib with obinutuzumab may be safe tolerable and/or effective in treating patients with MCL. conditions: Mantle Cell Lymphoma studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 27 type: ESTIMATED name: Biospecimen Collection name: Bone Marrow Biopsy name: Computed Tomography name: Echocardiography name: FDG-Positron Emission Tomography name: Glofitamab name: Ibrutinib name: Magnetic Resonance Imaging name: Obinutuzumab measure: Incidence of dose-limiting toxicities (DLT) measure: Proportion of participants who achieve a complete response (CR) measure: Incidence of grade 3 or above adverse events (AEs) measure: Proportion of patients treated with tocilizumab (TCZ) measure: Number of doses of TCZ per participant measure: Objective response rate (ORR) measure: Progression-free survival (PFS) measure: Duration of response (DOR) measure: Duration of complete response (DOCR) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: OHSU Knight Cancer Institute city: Portland state: Oregon zip: 97239 country: United States name: Knight Cancer Clinical Trials Hotline role: CONTACT phone: 503-494-1080 email: trials@ohsu.edu name: Stephen E. Spurgeon role: PRINCIPAL_INVESTIGATOR lat: 45.52345 lon: -122.67621 hasResults: False
nctId: NCT06357663 id: Pro00071128 briefTitle: Subtle Energy Transmission and Tao Calligraphy Mindfulness in Telomere Length in Peripheral Blood Leukocytes overallStatus: ACTIVE_NOT_RECRUITING date: 2023-06-15 date: 2025-12-31 date: 2025-12-31 date: 2024-04-10 date: 2024-04-16 name: Sha Research Foundation class: OTHER briefSummary: Effect of Subtle Energy Transmission and Tao Calligraphy Mindfulness Practice on Telomere Length in Peripheral Blood Leukocytes A Follow-up Pilot Study
* Practice the Mindfulness with Tao Calligraphy daily 1 hour in the morning and 1 hour in the evening. conditions: Telomere Length conditions: Quality of Life studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: The study will be performed as a Pilot follow-up study, should the 0 Hypothesis be successfully rejected, this study will be followed by a formal Double Blind Randomized Crossover Study.
Every subject who is accepted into the study, will have blood sample taken for analysis and will fill Rand SF 36 Questionnaire. Afterwards, will receive transmission of subtle energy by Zhi Gang Sha (or his designee) and will be instructed on how to practice mindfulness with Tao Calligraphy. primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 12 type: ACTUAL name: Mindfulness practice with Calligraphy measure: Telomere Length in Peripheral blood leukocytes measure: Quality of Life by John Ware's SF-36 Quality of Life questionnaire (that produces eight scores with 0-to-100 scale, 100 being the best possible outcome). sex: ALL minimumAge: 60 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Sha Research Foundation (Branch) city: North Vancouver state: British Columbia zip: V7R 1P5 country: Canada lat: 49.31636 lon: -123.06934 typeAbbrev: Prot_SAP hasProtocol: True hasSap: True hasIcf: False label: Study Protocol and Statistical Analysis Plan date: 2023-04-10 uploadDate: 2024-03-28T15:14 filename: Prot_SAP_000.pdf size: 428331 hasResults: False
nctId: NCT06357650 id: CSQ-2024-001 briefTitle: Collaborative Open Research Initiative Study (CORIS-1) acronym: CORIS-1 overallStatus: NOT_YET_RECRUITING date: 2024-06-01 date: 2024-12-31 date: 2025-06-30 date: 2024-04-10 date: 2024-04-10 name: Chisquares Incorporated class: INDUSTRY briefSummary: The Collaborative Open Research Initiative Study (CORIS) is a groundbreaking international research endeavor aimed at exploring vital topics within the field of health professions education. At its core, CORIS embodies the spirit of inclusivity by opening its doors to contributors from all corners of the globe, putting the power of research into the hands of the global community and fostering an environment of open collaboration and meaningful contribution. We invite anyone and everyone to join as collaborators and suggest questions for inclusion in the survey, ensuring that the research process is enriched by diverse perspectives. As a collaborator, you will not only have the opportunity to actively engage in survey design, question formulation, and the entire research process from start to finish, but also gain the prospect of achieving valuable publications, which may boost your professional career. conditions: Patient Engagement conditions: COVID-19 conditions: Preventable Disease, Vaccine conditions: Burnout, Professional conditions: Emerging Infectious Disease conditions: Artificial Intelligence conditions: Climate Change conditions: Online Education conditions: Mental Health Issue conditions: Substance Use Disorders studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: CROSS_SECTIONAL count: 15000 type: ESTIMATED name: No intervention. This is an observational study measure: Percentage of health professions schools implementing changes in patient care strategies before versus after the COVID-19 pandemic. measure: Percentage of personnel in health professions education with adequate epidemic preparedness and readiness. measure: Percentage of faculty and staff in health professions schools experiencing burnout. measure: Percentage of healthcare professionals who report the integration and utilization of artificial intelligence (AI) in their education and practice. measure: Percentage of participants expressing positive attitudes and perceptions towards climate change and the role of individuals and society in mitigating it. measure: Percentage of participants reporting effectiveness and challenges of remote learning and online education in health professions schools. measure: Percentage of personnel within health professions education reporting substance use behaviors and their implications. sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06357637 id: 59/2023 briefTitle: Abdominal Circumference Measure in Caesarian Section acronym: ACirCuS overallStatus: RECRUITING date: 2023-12-01 date: 2024-05-01 date: 2024-05-31 date: 2024-04-10 date: 2024-04-10 name: CHU Mohammed VI Marrakech class: OTHER briefSummary: The goal of this observational study is to evaluate preoperative measures of abdominal circumference in patients admitted for a cesarean section. The main questions it aims to answer are:
* Can preoperative abdominal circumference predict the occurrence of maternal hypotension during cesarean section Participants will be examined preoperatively in terms of visibility and palpation of spinous processes, abdominal circumference will be measured in the supine and sitting positions with other clinical parameters. Spinal anesthesia will be performed by the same experienced anesthesiologist with a standardized procedure. The number of skin punctures, needle reorientations, traumatic Cerebrospinal fluid, need for a paramedian approach or failure will be recorded. Maternal blood pressure and vasopressor requirements will also be monitored. conditions: Anesthesia, Spinal conditions: Cesarean Section studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 100 type: ESTIMATED name: Measure of abdominal circumference measure: Number of patients with difficult spinal anesthesia measure: Rate of Maternal hypotension sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: CHU Mohammed VI status: RECRUITING city: Marrakech zip: 40000 country: Morocco name: MERYEM ESSAFTI, MD role: CONTACT phone: +212662393700 email: essafti.m@gmail.com name: MARINA BOKOBA, MD role: CONTACT phone: +242065166209 email: marinande00@gmail.com name: MERYEM ESSAFTI, MD role: PRINCIPAL_INVESTIGATOR name: MARINA NDE BOKOBA, MD role: SUB_INVESTIGATOR lat: 31.63416 lon: -7.99994 typeAbbrev: Prot hasProtocol: True hasSap: False hasIcf: False label: Study Protocol date: 2024-01-10 uploadDate: 2024-01-23T03:56 filename: Prot_000.pdf size: 162775 typeAbbrev: ICF hasProtocol: False hasSap: False hasIcf: True label: Informed Consent Form date: 2024-04-01 uploadDate: 2024-04-06T11:11 filename: ICF_001.pdf size: 350456 hasResults: False